The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
There are 160–170 million people with chronic hepatitis C virus (HCV) infection worldwide. The marketing of protease inhibitors (PIs) has been a milestone in the history of HCV therapy. In phase III studies, up to 75% of the patients achieved a sustained virological response (SVR) after triple therapy with pegylated‐interferon (PEG‐IFN)‐α, ribavirin (RBV) and boceprevir (BOC). However, triple regimens...
The world changed in 2011 for the hepatitis C virus (HCV), with the FDA’s and EMA’s approval of the two new first generation protease inhibitors for the treatment of hepatitis C, boceprevir and telaprevir. Viral response rates have increased for genotype 1 patients by 2–6 fold compared to the thus far standard of care with pegylated interferon alfa plus ribavirin. Response very much depends on whether...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.